Purpose: In patients with stomach cancer, the inflammatory response of the host, and tumor markers, play essential roles in determining the prognosis. This study aimed to predict prognosis in previously untreated gastric cancer patients using inflammatory markers. Materials and Methods: This retrospective study evaluated 100 patients with stomach cancer, treated between 2015 and 2018. Pre-and postoperative blood samples were analyzed for the neutrophil/lymphocyte ratio (NLR), the platelet/lymphocyte ratio (PLR), the systemic inflammatory index (SII), and other immune markers. Results: The survival rate was significantly higher in patients with an SII level &amp;lt; 1190.4 compared to patients with an SII level &amp;gt; 1190.4 (p &amp;lt; 0.05). The disease-free survival was 47.7 months in the group with a low SII (84.4%) and 37 months in the group with a high SII (80%). In the ROC analysis, the AUC for NLR, PLR, and SII was 0.611, 0.65, and 0.64, respectively (p-values: 0.058, 0.010, and 0.011). The preoperative values were not significant; however, the postoperative values were significant for prognosis. Conclusion: During the pre-and postoperative periods, analysis of the inflammatory markers (NLR, PLR, and SII) guides the treatment and follow-up as much as the histopathological features of the tumor. High NLR and SII levels shortened overall survival during the 4-year follow-up.
Author(s): Nilufer Bulut, Berrak Sahtiyanci